The Greater Cannabis Company, Inc. (GCAN)

Market Cap	377.97K -6.1%
Revenue (ttm)	n/a
Net Income	-712.72K
EPS	-0.98
Shares Out	944.94K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,842
Average Volume	14,220
Open	0.2000
Previous Close	0.2000
Day's Range	0.1637 - 0.4199
52-Week Range	0.0360 - 3.6000
Beta	0.55
RSI	50.49
Earnings Date	Apr 2, 2026

About GCAN

The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease, and other neuropsychiatric disorders. The company was founded in 2014 and is based in Baltimore, Maryland.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: GCAN